AstraZeneca increases investment into cancer biomarkers
This article was originally published in Clinica
AstraZeneca has doubled its investment in Cancer Research UK's biomarker research programme. The project aims to assess whether AstraZeneca's drug candidates kill tumour cells and/or prevent angiogenesis – the growth of new blood vessels. The cash injection will allow the London-based charity to increase its capacity for biomarker discovery and evaluation, from 14,000 biomarker assays per year to up to 30,000 per year. The value of the investment was not disclosed. Meanwhile, Cancer Research UK presented results from a study at the NCRI Cancer Conference in Birmingham, UK, today, which found that levels of circulating tumour cells (CTCs) can be used to measure the effects of current lung cancer drugs. CTC levels were higher in the blood of patients whose cancer had spread, and dropped after chemotherapy.
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.